

Our Vision

Become a first-tier enterprise in the global mainstream pharmaceutical and healthcare market.

Our Mission

Better health for families worldwide.

Contents

2	C	a	m
4	a	a	■
5	▼	a	a m D a A a
35	§	a	D
41	m	C	C a § a m f
42	m	C	C a § a m C m m
43	m	C	C a § a m a a f
45	m	C	C a § a m C a
47	m	C	C a § a m Ca w
49	▲	m	C C a a a § a m
78	D		

Directors

Executive Directors

- ▼ . C (陳啟宇) (n)
- ▼ . 方 (姚方) (- n)
- ▼ . 芳 (吳以芳) (n)

Non-executive Directors

- ▼ . 亮 (徐曉亮)
- ▼ . 平 (龔平)¹
- ▼ . D (潘東輝)¹
- ▼ . 峰 (梁劍峰)²
- ▼ . C (王燦)³
- ▼ . 寧 (沐海寧)⁵

Independent Non-executive Directors

- ▼ . 江 (江憲)
- D . 6.8964 mC2095 02 1406 / 1 1 .881881 ▼ . 5 m (▼ .) /CB7050B050AD1110 08A4 / 1

Stock Abbreviation

公司A

Share Listing

公司A 股票代码 : 600196
公司B 股票代码 : 02196

A Share Registrar and Transfer Office in the PRC

公司A 在 DCC (DCC) 注册
公司B 在 B 注册
166 公司A 在 D 注册
公司C 在 C 注册

H Share Registrar and Transfer Office in Hong Kong

公司A 在 54, 183 注册
公司B 在 183 注册

Company's Website

://www. 公司A. 公司B

- 1 A 30 2020
- 2 17 2020
- 3 21 2020
- 4 A 21 2020
- 5 30 2020
- 6 A 30 2020

Financial

		Six months ended 30 June	
		2020	2019
		RMB million	B m
Operating results			
		13,965	14,085
		7,749	8,486
		1,292	1,490
		2,302	2,196
		1,715	1,516
		3,566	3,483
Profitability			
		55.49%	60.25%
		9.25%	10.58%
		13.67%	12.92%
Earnings per share (basic) 0.12 (2019: 0.11)		0.12	0.11
Earnings per share (diluted) 0.11 (2019: 0.10)		0.11	0.10

D A

D. 2019. D. 21.35% B3,931 m B4,998 m

[illegible]

D	F	A	A	A	8.03%	B699 m	B760 m
2019.							

[illegible]

D
 13.10%
 2019, B1,715
 2019- C
 (Ba)
 (2,000)
 B224
 B100
 (3)

DEBT STRUCTURE, LIQUIDITY AND SOURCES OF FUNDS

Total Debts

A 30 2020, 823,358 m 821,137 m 31 D 2019 m

Management

D A

Maturity Structure of Outstanding Debts

	30 June 2020	31 D 2019
1	12,405	8,560
2	7,834	6,860
5	2,633	5,396
5	483	321
	23,358	21,137

Available Facilities

A 30 2020, B9,750 m, B32,709 m
B48,320 m B15,611 m

Collateral and Pledged Assets

A 30 2020, B217
B134 m B396 m (31 D 2019: B303 m),
B5 m B4 m

D 16

Cash Flow

2019.

	January – June 2020	2019
	1,461	1,450
	(2,379)	(1,079)
	827	(496)
	(91)	(125)
	8,284	7,175
	8,177	7,052

Management

D A

D 0.85% ▼B13,965 2019. 7.97% ▼B9,952 2019. 47.18% ▼B2,639 2019. 6.85% ▼B1,359 2019. 38.04% ▼B8,098 9.96%

D ▼B4,071 29.15% ▼B9,894

D

: C : ▼B

Business segment	Revenue Jan – Jun 2020		2019	/ (%)
&D	9,952	10,814	7.97	
▼	2,639	1,793	47.18	
■	1,359	1,459	6.85	

D ▼B2,302 ▼B1,715 4.83% 13.10% 2019. (1) (2) (3) ▼B100 (4) ▼B224

(1) (2) (3) (4)

D 0.77% 2020 ▼B1,461 2019.

D &D ▼B1,689 25.02% ▼B1,204 ▼B355 41.81% 2019.

D

7.97% 2019.

▼B1,116 7.40% 9.54% 2019,

▼B1,115 &D 27.92% ▼B1,541

15.4% &D ▼B335

46.27% 2019 ▼B1,059 10.6%

[illegible]

$\frac{1}{\sqrt{2}}$

										Jan – Jun 2020	2019	2020
											(1)	(%)
Pharmaceutical manufacturing and R&D												
▼	▼	▼	▼	▼	▼	▼	▼	▼	▼	1,767	1,807	2.19
▼	▼	▼	▼	▼	▼	▼	▼	▼	▼	422	264	59.94
▼	▼	▼	▼	▼	▼	▼	▼	▼	▼	1,800	2,331	22.77
▼	▼	▼	▼	▼	▼	▼	▼	▼	▼	755	1,224	38.35
▼	▼	▼	▼	▼	▼	▼	▼	▼	▼	1,248	1,140	9.49
▼	▼	▼	▼	▼	▼	▼	▼	▼	▼	247	419	41.03
▼	▼	▼	▼	▼	▼	▼	▼	▼	▼	452	675	32.97

[illegible][illegible][illegible][illegible]

 A

Name of R&D project on drugs (products)		R&D stages as at the end of the Reporting Period in the PRC		R&D stages as at the end of the Reporting Period in other countries	
No.		R&D stage	Stage of clinical trial	R&D stage	Stage of clinical trial
1	5 A -189 (C ₁)	C			
2	C ₁ -411	C			
3	1-1501	C		C	
4	C ₁ -437	C		C	
5	1-159	C			
6	1-159	C			
7	1-1001 (1)	C		C	
8	D	C			
9	C ₁ -647 C ₁	A			
10	C ₁ -207	A			
11	C ₁ -011 C ₁	A			
12	C ₁ -338 (2)	A		A	

1: 5 A -189 (C₁) R&D stage C, Stage of clinical trial

2: A -159 (C₁) R&D stage C, Stage of clinical trial

Name of R&D project on drugs (products)		R&D stages in China as at the end of the Reporting Period		R&D stages in other countries as at the end of the Reporting Period	
No.	Type	R&D stage	Stage of clinical trial	R&D stage	Stage of clinical trial
1	B				
2	B				
3	B				
4	B				
5	B				

Management

D A

No.	Type	Name of R&D project on drugs (products)	R&D stages in China as at the end of the Reporting Period		R&D stages in other countries as at the end of the Reporting Period	
			R&D stage	Stage of clinical trial	R&D stage	Stage of clinical trial
6	B	■ 2 D ■ A	A			
7	B	■ 2 D ■ A	C			
8	B	■ A -C A-4 ■ A	A			
9	B	■ A - A ■ A	A			
10	B	■ A -CD20 ■ A	C			(4)
11	B	■ A - ■ A	A			
12	B	■ A - 2 ■ A (5)	C			A
13	B	■ A - ■ A (6)	C			A
14	B	■ A -D-1 ■ A (7)	C			A
15	B	■ A -D- 1 ■ A	A			C ()
16	B	■ 22 ■ A	C			
17	B	■ 55 ■ A	C			
18	B	■ 56 ■ A	A			
19	C	■ A -D-1 ■ A - ■ A	C			(10)

Management

D A

3: P A m a a a w m .

4: S m a a a a a a C v a .

5: A A a a a a P a w a C a; m , a a a a

6: A a a / a P C v a ; m , a a a a a a S .

7: A a a a a a m a a w a C a; a a a a a C

8: A a a a a a a B a w a a w a C a.

9: A a a a a a A a a .

10: S w a a a a w a C a.

10: a a m m a a a D-1 m a a a m a a - m a

m a a m w a a a a a C v a a a a a a a

m a a a m - m a w a , a a a a m a a a a a m a a

a a a m m .

A a P , m a &D a w:

No.	Type	Name of R&D project on drugs (products)	Indications	R&D stages as at the end of the Reporting Period in the PRC	Stage of clinical trial as at the end of the Reporting Period in the PRC
1	C m a	P A-824	a m a a C a a (D - B) m a a (D - B) w a a / w a	C a a	P a
2	C m a	A a m a v a a	m a a a a m m a a a w a a a a a a	C a a A a	P a
3	C m a	a a a	a w a m w a a a m a - a a a a a a C m m a a (1)	P a a P a a P a a	P a P a P a
4	C m a	B m a	m a m a a a a a a a a a	P a a P a a	P a P a
5	C m a	a a	P a C m a a	C a a	P a
6	C m a	a a	a a a a a a	P a a	P a

Interim Report 2020 17

Management

D A

D, the Company's management has conducted a comprehensive review of the Company's financial performance and operations for the period ended December 31, 2020. The Company's management has identified several key areas of concern, including the impact of the COVID-19 pandemic on the Company's operations and financial performance. The Company's management has also identified several key areas of opportunity, including the potential for growth in the Company's pharmaceutical business and the potential for expansion into new markets. The Company's management has taken several steps to address these concerns and opportunities, including the implementation of cost-cutting measures and the launch of new products. The Company's management believes that these steps will help to improve the Company's financial performance and operations in the future.

Medical Devices and Medical Diagnosis

D, the Company's management has conducted a comprehensive review of the Company's financial performance and operations for the period ended December 31, 2020. The Company's management has identified several key areas of concern, including the impact of the COVID-19 pandemic on the Company's operations and financial performance. The Company's management has also identified several key areas of opportunity, including the potential for growth in the Company's medical devices and medical diagnosis business. The Company's management has taken several steps to address these concerns and opportunities, including the implementation of cost-cutting measures and the launch of new products. The Company's management believes that these steps will help to improve the Company's financial performance and operations in the future.

D, the Company's management has conducted a comprehensive review of the Company's financial performance and operations for the period ended December 31, 2020. The Company's management has identified several key areas of concern, including the impact of the COVID-19 pandemic on the Company's operations and financial performance. The Company's management has also identified several key areas of opportunity, including the potential for growth in the Company's medical devices and medical diagnosis business. The Company's management has taken several steps to address these concerns and opportunities, including the implementation of cost-cutting measures and the launch of new products. The Company's management believes that these steps will help to improve the Company's financial performance and operations in the future.

D, the Company's management has conducted a comprehensive review of the Company's financial performance and operations for the period ended December 31, 2020. The Company's management has identified several key areas of concern, including the impact of the COVID-19 pandemic on the Company's operations and financial performance. The Company's management has also identified several key areas of opportunity, including the potential for growth in the Company's medical devices and medical diagnosis business. The Company's management has taken several steps to address these concerns and opportunities, including the implementation of cost-cutting measures and the launch of new products. The Company's management believes that these steps will help to improve the Company's financial performance and operations in the future.

D, the Company's management has conducted a comprehensive review of the Company's financial performance and operations for the period ended December 31, 2020. The Company's management has identified several key areas of concern, including the impact of the COVID-19 pandemic on the Company's operations and financial performance. The Company's management has also identified several key areas of opportunity, including the potential for growth in the Company's medical devices and medical diagnosis business. The Company's management has taken several steps to address these concerns and opportunities, including the implementation of cost-cutting measures and the launch of new products. The Company's management believes that these steps will help to improve the Company's financial performance and operations in the future.

Healthcare Services

D

2019.

▼B1,359 6.85% 2019;

▼B31 81.43% 2019, 2019,

▼B2 98.40% 2019.

C 3 4

37.8%

D

4,328

[illegible][illegible]

Pharmaceutical Distribution and Retail

項目	2020年	2019年	2018年	2017年	2016年	2015年	2014年	2013年	2012年	2011年	2010年	2009年	2008年	2007年	2006年	2005年	2004年	2003年	2002年	2001年	2000年	1999年	1998年	1997年	1996年	1995年	1994年	1993年	1992年	1991年	1990年	1989年	1988年	1987年	1986年	1985年	1984年	1983年	1982年	1981年	1980年	1979年	1978年	1977年	1976年	1975年	1974年	1973年	1972年	1971年	1970年	1969年	1968年	1967年	1966年	1965年	1964年	1963年	1962年	1961年	1960年	1959年	1958年	1957年	1956年	1955年	1954年	1953年	1952年	1951年	1950年	1949年	1948年	1947年	1946年	1945年	1944年	1943年	1942年	1941年	1940年	1939年	1938年	1937年	1936年	1935年	1934年	1933年	1932年	1931年	1930年	1929年	1928年	1927年	1926年	1925年	1924年	1923年	1922年	1921年	1920年	1919年	1918年	1917年	1916年	1915年	1914年	1913年	1912年	1911年	1910年	1909年	1908年	1907年	1906年	1905年	1904年	1903年	1902年	1901年	1900年	1899年	1898年	1897年	1896年	1895年	1894年	1893年	1892年	1891年	1890年	1889年	1888年	1887年	1886年	1885年	1884年	1883年	1882年	1881年	1880年	1879年	1878年	1877年	1876年	1875年	1874年	1873年	1872年	1871年	1870年	1869年	1868年	1867年	1866年	1865年	1864年	1863年	1862年	1861年	1860年	1859年	1858年	1857年	1856年	1855年	1854年	1853年	1852年	1851年	1850年	1849年	1848年	1847年	1846年	1845年	1844年	1843年	1842年	1841年	1840年	1839年	1838年	1837年	1836年	1835年	1834年	1833年	1832年	1831年	1830年	1829年	1828年	1827年	1826年	1825年	1824年	1823年	1822年	1821年	1820年	1819年	1818年	1817年	1816年	1815年	1814年	1813年	1812年	1811年	1810年	1809年	1808年	1807年	1806年	1805年	1804年	1803年	1802年	1801年	1800年	1799年	1798年	1797年	1796年	1795年	1794年	1793年	1792年	1791年	1790年	1789年	1788年	1787年	1786年	1785年	1784年	1783年	1782年	1781年	1780年	1779年	1778年	1777年	1776年	1775年	1774年	1773年	1772年	1771年	1770年	1769年	1768年	1767年	1766年	1765年	1764年	1763年	1762年	1761年	1760年	1759年	1758年	1757年	1756年	1755年	1754年	1753年	1752年	1751年	1750年	1749年	1748年	1747年	1746年	1745年	1744年	1743年	1742年	1741年	1740年	1739年	1738年	1737年	1736年	1735年	1734年	1733年	1732年	1731年	1730年	1729年	1728年	1727年	1726年	1725年	1724年	1723年	1722年	1721年	1720年	1719年	1718年	1717年	1716年	1715年	1714年	1713年	1712年	1711年	1710年	1709年	1708年	1707年	1706年	1705年	1704年	1703年	1702年	1701年	1700年	1699年	1698年	1697年	1696年	1695年	1694年	1693年	1692年	1691年	1690年	1689年	1688年	1687年	1686年	1685年	1684年	1683年	1682年	1681年	1680年	1679年	1678年	1677年	1676年	1675年	1674年	1673年	1672年	1671年	1670年	1669年	1668年	1667年	1666年	1665年	1664年	1663年	1662年	1661年	1660年	1659年	1658年	1657年	1656年	1655年	1654年	1653年	1652年	1651年	1650年
----	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------

2020,5	4.38%	-	-	B157,495	100
--------	-------	---	---	----------	-----

Management

D A

2020, 30, 7,047, B11,016, 24.59%.

2020, 23.59%.

2020, 23.59%.

Internal Integration and Operation Enhancement

D

4

B

D

A

2020, 23.59%.


(1) $\frac{1}{h}$

h

$$: \text{M} \quad \text{C} \quad : \quad \text{B}$$

Items	Amount for the period	Amount for the corresponding period of last year	Period-on-period change (%)	Reasons
Cash and cash equivalents	13,965	14,085	0.85	
Receivables	6,216	5,599	11.02	
Prepaid expenses and other receivables	3,931	4,998	21.35	1
Accounts payable	1,322	1,148	15.16	
Other payables	1,204	849	41.81	2
Income taxes payable	428	547	21.76	3
Financial assets at fair value through profit or loss	1,461	1,450	0.77	
Financial assets at fair value through other comprehensive income	-2,379	1,079	120.55	4
Financial liabilities at fair value through profit or loss	827	496	266.75	5

1: D

2: 

[illegible]

4: ∇^2 $\frac{1}{r}$ $\frac{1}{r^2}$ $\frac{1}{r^3}$ $\frac{1}{r^4}$ $\frac{1}{r^5}$ $\frac{1}{r^6}$ $\frac{1}{r^7}$ $\frac{1}{r^8}$ $\frac{1}{r^9}$ $\frac{1}{r^{10}}$

5: $\nabla^2 u = f$ in Ω , $u = 0$ on $\partial\Omega$. $f \in L^2(\Omega)$, $u \in H_0^1(\Omega)$. $\|u\|_{H_0^1(\Omega)} \leq C \|f\|_{L^2(\Omega)}$.

(2) &

&D

: m C : ▼ B

&D		1,204
&D	↩ ↩	485
↩ &D		1,689
↩ &D	↩ ↩ ↩ (%)	12.0
&D	↩ m↩ ↩ m↩ ↩ ↩ &D m ↩ ↩ ↩	
P	m ↩ m↩ ↩ m↩ ↩ ↩ &D m (%)	15.4
f	↩ &D ↩ ↩ (%)	28.69

D

D P , &D ↩ m↩ ↩ m↩ ↩ ↩ &D m m↩
 ▼B1,541 m , ↩ ↩ ▼B336 m 27.92% ↩ m↩
 2019, ↩ 15.4% m ↩ m↩ ↩ m↩ ↩ ↩ &D m .
 W ↩ ↩ m ↩ ↩ ↩ ↩ ↩ ↩ , &D W
 W↩ ↩ ↩ ↩ m m↩ ↩ m↩ ↩ ↩ . A ↩ m↩ m ,
 &D m↩ m ↩ , &D ↩ ↩ ↩ . A m↩
 m ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ , &D W ↩ ↩ ↩ ↩ .
 ↩ &D P ↩ ↩ W↩ m↩ ↩ &D
 ↩ m↩ ↩ , m↩ m ↩ ↩ ↩ ↩ m ↩ ↩ , ↩ ↩
 m ↩ ↩ ↩ ↩ m↩

B. Analysis of Segment and Regional Operations
(1)

: m C : B

Table with 7 columns: By segments, Revenue, Cost of sales, Gross profit margin (%), Period-on-period change in revenue (%), Period-on-period change in cost of sales (%), Period-on-period change in gross margin. Rows include &D, (1), and (2) segments.

Table with 7 columns: Products, Revenue, Cost of sales, Gross profit margin (%), Period-on-period change in revenue (%), Period-on-period change in cost of sales (%), Period-on-period change in gross margin. Rows include products (3), (4), (5), (6), (7), and A products.

		Principal operations by geographical locations				Period-on-period	
By geographical locations		Revenue	Cost of sales	Gross profit margin (%)	Period-on-period change in revenue (%)	change in cost of sales (%)	Period-on-period change in gross margin
C		9,894	4,093	58.63	8.30	11.40	↩ 7.32
↩		4,071	2,123	47.84	23.53	10.29	↩ 6.26
1: .63							↩

Management

D A A

C. Analysis of Major Subsidiaries and Investee Companies

(1)

: m C : ▼ B

Name of subsidiary	Nature of business	Major products or services	Registered capital	Total assets	Net assets	Revenue	Operating profit	Net profit
上海医药集团医药有限公司	医药研发、生产和销售	阿司匹林、D 、C、 C、	197	5,753	3,514	2,414	485	416
上海医药集团医药有限公司	医药研发、生产和销售	B、 、W、 、	440	5,176	2,770	2,825	441	369
上海医药集团医药有限公司	医药研发、生产和销售	、 、 、	1/A	6,956	5,645	1,476	562	419
上海医药集团医药有限公司	医药研发、生产和销售	A、D、B、 、C、 、	510	2,626	1,864	599	64	61

: 医药研发、生产和销售 医药研发、生产和销售 医药研发、生产和销售 医药研发、生产和销售 医药研发、生产和销售 医药研发、生产和销售 医药研发、生产和销售 医药研发、生产和销售 医药研发、生产和销售


: m C : ▼ B

Name of subsidiary	Nature of business	Major products or services	Registered capital	Total assets	Net assets	Revenue	Operating profit	Net profit
上海医药集团医药有限公司 (1)	医药研发、生产和销售	、	543	5,536	3,708	110	448	
C (2)	医药研发、生产和销售	、	50	2,528	1,728	686	41	
上海医药集团医药有限公司 (1)	医药研发、生产和销售	、 、	1/A	2,745	2,302	504	40	

1: 医药研发、生产和销售 医药研发、生产和销售 医药研发、生产和销售 医药研发、生产和销售 医药研发、生产和销售 医药研发、生产和销售 医药研发、生产和销售 医药研发、生产和销售 医药研发、生产和销售

2: 医药研发、生产和销售 医药研发、生产和销售 医药研发、生产和销售 医药研发、生产和销售 医药研发、生产和销售 医药研发、生产和销售 医药研发、生产和销售 医药研发、生产和销售 医药研发、生产和销售

$$: \text{M} \quad \text{C} \quad : \quad \text{B}$$

(3) 

$$: \text{M} \quad \text{C} \quad : \text{B}$$

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466
---	---	---	---	---	---	---	---	---	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

D A

29 2020,

१ C १ ■ १ , १ M १ , W १ M .

[illegible]
$$: \text{M} \quad \text{C} \quad : \quad \text{B}$$

Name of subsidiary	Disposed through	Net assets as at date of disposal	Net profit from beginning of Reporting Period to date of disposal	Date of disposal
C a ■ a	D a	0	29	a 2020

[illegible]

ମା -ବ ବ &D, ବ ମା^୧ ବ ବ ,
 ବ ବ ମା ବ ବ , - ବ , ବ ବ
 ବ ବ ମା ବ ବ ବ ବ ବ . ବ , ' , ବ ବ
 ମା , ମା ବ ବ ବ ବ ବ ବ ବ
 ବ ବ ବ ବ ବ ମା ବ ବ ବ .

[illegible]

A 30,925 m

[illegible][illegible]

[illegible]

২০২০, W অ ব ব , অ ব - অ ,
অ ম , অ ম অ অ , অ অ অ
অ ম ম - , ম - - - অ , - - অ , অ অ অ IC (
অ , অ অ অ). W অ অ অ অ অ
অ অ ম W অ . ম , W অ অ
IC W &D ম IC , ম ম অ অ অ অ

- W' a a a a M' W' -
 - a a , a a &D a a a a M' a M' .
 W' a a a a a W' a a M'a a M' a W' a a
 a a a M' M' M' C a a , M'a^K a a M' , a
 W' M' M' M' a M' a M'a a M'a a

[illegible][illegible][illegible]

D A

Healthcare Services

Pharmaceutical Distribution and Retail

Financing

3. Potential Risks

[illegible]

ମ ମ ଗ , &D ଗ ଗ - ମ ଗ ଗ , ଗ ଗ ଗ
ଗ ଗ ଗ ଗ ଗ ମ - ମ ଗ ଗ ମ ଗ ଗ
ଗ . ମ ଗ ମ ଗ ଗ K ମ ଗ ମ ଗ ମ
ଗ ଗ ଗ ଗ ଗ ମ ମ ଗ , ଗ ଗ ଗ ମ
ମ ଗ ମ ଗ ଗ ମ

D A

/

[illegible][illegible]

∇ a b m a b a b m a K
 , m a a b , a a m a a
 K , m a a a m a a m a a , a , a , a a

IV. Management risks

(1)

Management risks are risks that may affect the company's ability to achieve its business strategy and goals. These risks are categorized into strategic risks, operational risks, financial risks, and compliance risks. Strategic risks include risks related to the company's long-term vision and mission. Operational risks include risks related to the company's internal processes and systems. Financial risks include risks related to the company's financial performance and stability. Compliance risks include risks related to the company's adherence to applicable laws and regulations.

(2)

Management risks are risks that may affect the company's ability to achieve its business strategy and goals. These risks are categorized into strategic risks, operational risks, financial risks, and compliance risks. Strategic risks include risks related to the company's long-term vision and mission. Operational risks include risks related to the company's internal processes and systems. Financial risks include risks related to the company's financial performance and stability. Compliance risks include risks related to the company's adherence to applicable laws and regulations.

V. Foreign exchange risk

Foreign exchange risk is the risk that the value of a company's assets and liabilities will change due to fluctuations in the exchange rate of the company's functional currency against the currency of the assets and liabilities. This risk is typically managed through the use of foreign exchange derivatives, such as forward contracts, futures, and options.

VI. Force majeure risks

Force majeure risks are risks that are beyond the control of the company and may result in significant financial loss or damage to the company's reputation. These risks include natural disasters, war, and political instability.

4. Other Events

A. 2019 Shareholding Increase Plan of the Controlling Shareholder

A. 2019 Shareholding Increase Plan of the Controlling Shareholder. The Controlling Shareholder has announced a plan to increase its shareholding in the company by 19% in 2019. The plan is subject to the approval of the company's shareholders and the relevant regulatory authorities. The Controlling Shareholder has indicated that it will use a combination of cash and debt financing to fund the increase. The plan is expected to be completed by the end of 2019.

The Controlling Shareholder has also announced a plan to increase its shareholding in the company by 12% in 2019. The plan is subject to the approval of the company's shareholders and the relevant regulatory authorities. The Controlling Shareholder has indicated that it will use a combination of cash and debt financing to fund the increase. The plan is expected to be completed by the end of 2019.

The Controlling Shareholder has also announced a plan to increase its shareholding in the company by 2% in 2019. The plan is subject to the approval of the company's shareholders and the relevant regulatory authorities. The Controlling Shareholder has indicated that it will use a combination of cash and debt financing to fund the increase. The plan is expected to be completed by the end of 2019.

The Controlling Shareholder has also announced a plan to increase its shareholding in the company by 16,369,500 shares in 2019. The plan is subject to the approval of the company's shareholders and the relevant regulatory authorities. The Controlling Shareholder has indicated that it will use a combination of cash and debt financing to fund the increase. The plan is expected to be completed by the end of 2019.

The Controlling Shareholder has also announced a plan to increase its shareholding in the company by 0.64% in 2019. The plan is subject to the approval of the company's shareholders and the relevant regulatory authorities. The Controlling Shareholder has indicated that it will use a combination of cash and debt financing to fund the increase. The plan is expected to be completed by the end of 2019.

D A

h -

2020, 2.20%.

A. A. C. M. A. - M. M. A. A. A. M. - M.
 A. A. (S. 2020 A. S. C. (325) A. A. A.
 (S. 2020 A. S. 677) A. A. 2020, A. M. A. C. M. A. '
 - M. M. A. A. A. A. M. - M. B5. S. A. M. A. 2 A.
 M. M. M. A. A. A. A. A. , A. C. M. A. M. A. A. W.

A 2020, C C A a C a B a a

A 2020, C C A B C B
A () C , * (2020 .701), W
C m a ' a a B5 a a a a
a 24 m m a G C' a a a a C m a m a a w

30_D m 2019, 8 a a , am a -

[illegible]

Statutory D

SUPERVISORS

A 任 (任倩) (女) C 曹根興 (曹根興) 管一民 (管一民)

- ▼ . 任倩 (任倩) (女)
- ▼ . 曹根興 (曹根興)
- ▼ . 管一民 (管一民)

CHANGE OF INFORMATION OF DIRECTORS AND SUPERVISORS

▼ . C 任倩 (任倩) (女) D 曹根興 (曹根興) Ba 管一民 (管一民) (01761), 2020.

▼ . 任倩 (任倩) (女) D 曹根興 (曹根興) 管一民 (管一民) (01818), 2020.

▼ . 任倩 (任倩) (女) D 曹根興 (曹根興) 管一民 (管一民) (00755), 2020.

▼ . 任倩 (任倩) (女) D 曹根興 (曹根興) 管一民 (管一民) (600834), 2020.

D. 任倩 (任倩) (女) C 曹根興 (曹根興) 管一民 (管一民) (長飛光纖光纜股份有限公司) (061869, 06869), 2020.

▼ . 任倩 (任倩) (女) D 曹根興 (曹根興) 管一民 (管一民) (600623), 2020.

任倩 (任倩) (女) D 曹根興 (曹根興) 管一民 (管一民) (13.51(2))

SHARE INCENTIVE SCHEMES

Gland Pharma Share Option Incentive Scheme

任倩 (任倩) (女) C 曹根興 (曹根興) 管一民 (管一民) (25 2019).

任倩 (任倩) (女) C 曹根興 (曹根興) 管一民 (管一民) (170,444 1.1% 2020).

27 2019, 154,950 103 102 154,650 1%

5,420

17 2020, (1) (10) A

D

Participant	Date of Grant (dd-mm-yyyy)	Vesting Date (dd-mm-yyyy) ⁽¹⁾	Option share ⁽¹⁾	Exercise Period ⁽¹⁾	Outstanding options as at 1 January 2020	Adjusted during the Reporting Period ⁽²⁾	Exercise price per share ⁽³⁾	Forfeited or lapsed during the reporting period ⁽⁴⁾	Outstanding options as at 30 June 2020
M	27-6-2019	26-6-2020		26-6-2020 26-6-2029	151,350	1,362,150	1.542	(20,000)	1,493,500
		31-3-2021	40%	31-3-2021 26-6-2029					
		31-3-2022		31-3-2022 26-6-2029					
		31-3-2021	30%	31-3-2021 26-6-2029					
		31-3-2022		31-3-2022 26-6-2029					
		31-3-2022	30%	31-3-2022 26-6-2029					

- (1) 17 2020.
- (2) 17 2020.
- (3) 20,000
- (4) D
- (5) D

INTERESTS AND SHORT POSITIONS OF SUBSTANTIAL SHAREHOLDERS IN SHARES AND UNDERLYING SHARES

As at 30 June 2020, the interests and short positions of the substantial shareholders in the shares and underlying shares of the Company, as far as they are known to the Company, are as follows:

Name of Shareholders	Nature of interest	Class of Shares	Number of Shares ⁽¹⁾	Approximate percentage of Shares in relevant class of Shares
■	B	■	48,803,000 () ⁽²⁾	8.84%
■	B	AS	938,095,290 () ⁽²⁾	46.65%
■		■	48,803,000 () ⁽²⁾	8.84%
■		AS	938,095,290 () ⁽²⁾	46.65%
■		■	48,803,000 () ⁽²⁾	8.84%
■		AS	938,095,290 () ⁽²⁾	46.65%
■		■	48,803,000 () ⁽²⁾	8.84%
■		AS	938,095,290 () ⁽²⁾	46.65%
■		■	48,803,000 () ⁽²⁾	8.84%
■		AS	938,095,290 () ⁽²⁾	46.65%
■		■	48,803,000 () ⁽²⁾	8.84%
■		AS	938,095,290 () ⁽²⁾	46.65%
■		■	114,075 ()	0.01%
■		■	38,723,000 ()	7.02%
■		■	38,707,016 ()	7.01%
■		■	28,195,990 ()	5.11%
■		■	782,000 ()	0.14%

Notes:

(1) () : ()

(2) The percentage of shares held by the substantial shareholders is calculated based on the total number of shares of the Company in issue as at 30 June 2020, which is 554,000,000 shares. The percentage of shares held by the substantial shareholders is 71.09% for the shares of the Company and 85.29% for the underlying shares of the Company.

DIRECTORS' AND SUPERVISORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

During the period from 1 January 2020 to 30 June 2020, none of the directors or supervisors of the Company has exercised any rights to acquire shares or debentures of the Company.

C ମା ଗା C ଗା ମା C ଗା ଗା ଗା .

COMPLIANCE WITH THE CG CODE

[illegible][illegible]

21 ଡିସେମ୍ବର 2020, ସୋମବାର । ପୃଷ୍ଠା ୧୫ ।

[illegible]

A $\frac{P}{Q}$, a mm C $m \cdot a$ m $P \cdot Q \cdot a$ a ($a \cdot ma$), a -
D $\frac{P}{Q} \cdot a$ a, a - D $\frac{P}{Q} \cdot a$ a - D .

$\frac{C}{m} = \frac{B}{n}$

Chen Qiyu

25 A 2020

Interim Condensed Consolidated



For the six months ended 30 June 2020

		For the six months ended 30 June	
		2020	2019
		RMB'000	B'000
		(Unaudited)	()
REVENUE	5	13,965,179	14,085,146
C		(6,215,872)	(5,598,983)
		7,749,307	8,486,163
	6	180,429	109,724
		(3,931,067)	(4,998,448)
		(1,322,239)	(1,147,889)
		(1,204,425)	(849,383)
		(42,765)	(21,918)
	7	603,622	389,686
		(52,138)	(45,617)
		96,436	86,650
	8	(427,878)	(546,940)
		(46,558)	(25,933)
		698,964	760,055
PROFIT BEFORE TAX	9	2,301,688	2,196,150
	10	(392,081)	(376,521)
PROFIT FOR THE PERIOD		1,909,607	1,819,629
		1,714,710	1,516,120
		194,897	303,509
		1,909,607	1,819,629
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	12		
Ba		RMB0.67 Yuan	▼ B0.59
D		RMB0.67 Yuan	▼ B0.59

Interim Condensed Consolidated

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. 30 2020

For the six months ended 30 June

	2020 RMB'000 (Unaudited)	2019 B'000 ()
PROFIT FOR THE PERIOD	1,909,607	1,819,629
OTHER COMPREHENSIVE (LOSS)/INCOME		
Net other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods	(227,651)	70,799
Net other comprehensive income/(loss) that will not be reclassified to profit or loss in subsequent periods	72,684	(26,824)
OTHER COMPREHENSIVE (LOSS)/INCOME FOR THE PERIOD, NET OF TAX	(154,967)	43,975
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	1,754,640	1,863,604
Attributable to:		
Parent Company	1,660,547	1,544,923
Non-controlling interests	94,093	318,681
	1,754,640	1,863,604

Interim Condensed Consolidated

Financial Statements

30 June 2020

		30 June 2020 RMB'000 (Unaudited)	31 Dec 2019 RMB'000 (Audited)
NON-CURRENT ASSETS			
Property, plant and equipment	13	11,313,846	10,720,960
Intangible assets		2,389,837	2,454,742
Investments in subsidiaries		9,093,050	9,013,990
Investments in associates		9,238,300	9,036,246
Financial assets at fair value through profit or loss		356,204	381,332
Financial assets at fair value through other comprehensive income		21,712,444	20,491,557
Prepaid expenses and deposits		60,945	107,709
Other non-current assets		1,851,891	1,983,155
Deferred tax assets		236,457	196,095
		1,300,703	1,273,605
		57,553,677	55,659,391
CURRENT ASSETS			
Financial assets at fair value through profit or loss	14	4,561,539	3,940,537
Financial assets at fair value through other comprehensive income		5,271,488	4,607,722
Accounts receivable		1,628,029	1,420,087
Prepaid expenses and deposits		992,812	456,651
Other current assets		354,915	445,103
Deferred tax assets		9,750,416	9,533,268
		22,559,199	20,403,368
CURRENT LIABILITIES			
Accounts payable	15	2,864,017	2,397,315
Other payables and provisions		6,116,649	5,376,193
Contract liabilities	16	12,404,601	8,560,202
Financial liabilities at fair value through profit or loss		138,571	143,786
Financial liabilities at fair value through other comprehensive income		527,652	503,683
Other current liabilities		487,052	452,587
		22,538,542	17,433,766
NET CURRENT ASSETS		20,657	2,969,602
TOTAL ASSETS LESS CURRENT LIABILITIES		57,574,334	58,628,993

		30 June 2020 RMB'000 (Unaudited)	31 Dec 2019 RMB'000 (Audited)
NON-CURRENT LIABILITIES			
Long-term debt	16	10,953,518	12,576,907
Long-term equity investments		369,340	410,188
Derivative financial instruments		2,928,227	2,994,048
Deferred income		417,091	417,345
Other non-current liabilities		2,891,682	2,860,170
Other non-current liabilities		215,655	223,009
		17,775,513	19,481,667
Net assets		39,798,821	39,147,326
EQUITY			
Equity attributable to owners of the parent			
Capital		2,562,899	2,562,899
Reserves		30,419,792	29,268,280
		32,982,691	31,831,179
Non-controlling interests		6,816,130	7,316,147
Total equity		39,798,821	39,147,326

Chen Qiyu

Wu Yifang

S a m C a

For the six months ended 30 June 2020

	Attributable to owners of the parent								Non-controlling interests RMB'000	Total equity RMB'000
	Share capital RMB'000	Share premium RMB'000	Fair value reserve RMB'000	Statutory surplus reserve RMB'000	Other reserve RMB'000	Exchange fluctuation reserve RMB'000	Retained profits RMB'000	Total RMB'000		
At 1 January 2020 (A)	2,562,899	11,385,162*	(35,546)*	2,523,799*	899,356*	(420,878)*	14,916,387*	31,831,179	7,316,147	39,147,326
Profit for the year	—	—	—	—	—	—	1,714,710	1,714,710	194,897	1,909,607
Other comprehensive income	—	—	—	—	—	—	—	—	—	—
Change in fair value of equity instruments	—	—	3,819	—	—	—	—	3,819	(68)	3,751
Change in fair value of financial assets at fair value through profit or loss	—	—	96,891	—	—	—	—	96,891	—	96,891
Change in fair value of financial assets at fair value through other comprehensive income	—	—	—	—	—	(154,873)	—	(154,873)	(100,736)	(255,609)
Dividends paid	—	—	100,710	—	—	(154,873)	1,714,710	1,660,547	94,093	1,754,640
At 31 December 2020 (A)	—	—	—	—	159,607	—	—	159,607	(521,291)	(361,684)
Profit for the year	—	—	—	—	(784)	—	—	(784)	62	(722)
Other comprehensive income	—	—	—	—	(2,433)	—	—	(2,433)	—	(2,433)
Change in fair value of equity instruments	—	—	—	—	—	—	—	—	56	56
Change in fair value of financial assets at fair value through profit or loss	—	—	—	—	—	—	—	—	24,495	24,495
Change in fair value of financial assets at fair value through other comprehensive income	—	—	—	—	—	—	—	—	(241,721)	(241,721)
Dividends paid	—	—	—	—	—	—	—	—	162,645	162,645
At 31 December 2021 (A)	—	—	—	—	5,346	—	—	5,346	(18,356)	(13,010)
Profit for the year	—	—	—	—	329,734	—	—	329,734	—	329,734
Other comprehensive income	—	—	—	—	—	—	(1,000,505)	(1,000,505)	—	(1,000,505)
Change in fair value of equity instruments	—	—	107,320	—	—	—	(107,320)	—	—	—
At 30 September 2020 (A)	2,562,899	11,385,162*	172,484*	2,523,799*	1,390,826*	(575,751)*	15,523,272*	32,982,691	6,816,130	39,798,821

*		▼	B30,419,792,000 (31 D	▼	2019: B29,268,280,000)	▼ ▼ ▼
---	--	---	-----------------------	---	------------------------	-------

Interim Condensed Consolidated

Financial Statements

30 2020

		A										B	
		Revenue		Cost of Sales		Gross Profit		Operating Expenses		Operating Profit		Operating Profit	
		YTD	YTD	YTD	YTD	YTD	YTD	YTD	YTD	YTD	YTD	YTD	YTD
		B'000	B'000	B'000	B'000	B'000	B'000	B'000	B'000	B'000	B'000	B'000	B'000
A 1 2019 (A)		2,563,061	11,386,711*	(1,711)	30,105*	2,374,998*	(701,196)*	(293,315)*	12,562,197*	27,920,850	5,614,977	33,535,827	
C 2019									1,516,120	1,516,120	303,509	1,819,629	
D 2019													
E 2019													
F 2019													
G 2019													
H 2019													
I 2019													
J 2019													
K 2019													
L 2019													
M 2019													
N 2019													
O 2019													
P 2019													
Q 2019													
R 2019													
S 2019													
T 2019													
U 2019													
V 2019													
W 2019													
X 2019													
Y 2019													
Z 2019													
AA 2019													
AB 2019													
AC 2019													
AD 2019													
AE 2019													
AF 2019													
AG 2019													
AH 2019													
AI 2019													
AJ 2019													
AK 2019													
AL 2019													
AM 2019													
AN 2019													
AO 2019													
AP 2019													
AQ 2019													
AR 2019													
AS 2019													
AT 2019													
AU 2019													
AV 2019													
AW 2019													
AX 2019													
AY 2019													
AZ 2019													
BA 2019													
BB 2019													
BC 2019													
BD 2019													
BE 2019													
BF 2019													
BG 2019													
BH 2019													
BI 2019													
BJ 2019													
BK 2019													
BL 2019													
BM 2019													
BN 2019													
BO 2019													
BP 2019													
BQ 2019													
BR 2019													
BS 2019													
BT 2019													
BU 2019													
BV 2019													
BW 2019													
BX 2019													
BY 2019													
BZ 2019													
CA 2019													
CB 2019													
CC 2019													
CD 2019													
CE 2019													
CF 2019													
CG 2019													
CH 2019													
CI 2019													
CJ 2019													
CK 2019													
CL 2019													
CM 2019													
CN 2019													
CO 2019													
CP 2019													
CQ 2019													
CR 2019													
CS 2019													
CT 2019													
CU 2019													
CV 2019													
CW 2019													
CX 2019													
CY 2019													
CZ 2019													
DA 2019													
DB 2019													
DC 2019													
DD 2019													
DE 2019													
DF 2019													
DG 2019													
DH 2019													
DI 2019													
DJ 2019													
DK 2019													
DL 2019													
DM 2019													
DN 2019													
DO 2019													
DP 2019													
DQ 2019													
DR 2019													
DS 2019													
DT 2019													
DU 2019													
DV 2019													
DW 2019													
DX 2019													
DY 2019													
DZ 2019													
EA 2019													
EB 2019													
EC 2019													
ED 2019													
EE 2019													
EF 2019													
EG 2019													
EH 2019													
EI 2019													
EJ 2019													
EK 2019													
EL 2019													
EM 2019													
EN 2019													
EO 2019													
EP 2019													
EQ 2019													
ER 2019													
ES 2019													
ET 2019													
EU 2019													
EV 2019													
EW 2019													
EX 2019													
EY 2019													
EZ 2019													
FA 2019													
FB 2019													
FC 2019													
FD 2019													
FE 2019													
FF 2019													
FG 2019													
FH 2019													
FI 2019													
FJ 2019													
FK 2019													
FL 2019													
FM 2019													
FN 2019													
FO 2019													
FP 2019													
FQ 2019													
FR 2019													
FS 2019													
FT 2019													
FU 2019													
FV 2019													
FW 2019													
FX 2019													
FY 2019													
FZ 2019				</									

Interim Condensed Consolidated



For the six months ended 30 June 2020

		For the six months ended 30 June	
		2020	2019
		RMB'000	B'000
		(Unaudited)	()
Cash and cash equivalents		1,928,625	1,849,335
Less: cash equivalents		(467,328)	(399,147)
Total cash and cash equivalents		1,461,297	1,450,188
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of property, plant and equipment		(1,904,148)	(2,040,985)
Disposal of property, plant and equipment		(8,400)	(133,162)
Disposal of subsidiaries		(192,431)	(174,524)
Disposal of associates		(435,607)	(109,283)
Disposal of investments		151,917	35,418
Disposal of financial assets		474,449	642,245
Disposal of other financial assets		—	2,296
Disposal of intangible assets		67,961	41,866
Disposal of other assets		—	1,039
Disposal of other financial assets		18,718	20,053
Disposal of other assets		1,708	—
Disposal of other financial assets		5,439	26,015
Disposal of other financial assets		50,228	—
(Disposal of) / Disposal of other financial assets		(570,138)	570,562
Disposal of other financial assets		(38,629)	39,801
Total cash flows from investing activities		(2,378,933)	(1,078,659)

Interim Condensed Consolidated

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
30 2020

Notes to Interim Condensed Consolidated

30 June 2020

30 June 2020

1. CORPORATE AND GROUP INFORMATION

The Group is a company incorporated in the Cayman Islands. The Group's principal place of business is in Hong Kong. The Group's financial statements are prepared in accordance with the Hong Kong Financial Reporting Standards. The Group's financial statements are audited by the PricewaterhouseCoopers Chartered Accountants.

The Group's financial statements are prepared in accordance with the Hong Kong Financial Reporting Standards. The Group's financial statements are audited by the PricewaterhouseCoopers Chartered Accountants.

The Group's financial statements are prepared in accordance with the Hong Kong Financial Reporting Standards. The Group's financial statements are audited by the PricewaterhouseCoopers Chartered Accountants.

2. BASIS OF PREPARATION

The Group's financial statements are prepared in accordance with the Hong Kong Financial Reporting Standards. The Group's financial statements are audited by the PricewaterhouseCoopers Chartered Accountants.

3. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The Group's financial statements are prepared in accordance with the Hong Kong Financial Reporting Standards. The Group's financial statements are audited by the PricewaterhouseCoopers Chartered Accountants.

The Group's financial statements are prepared in accordance with the Hong Kong Financial Reporting Standards. The Group's financial statements are audited by the PricewaterhouseCoopers Chartered Accountants.

Notes to Interim Condensed Consolidated

2020

30

3. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (Continued)

2020

(a) Amended the Company's accounting policy for the recognition and measurement of financial assets and liabilities. The Company's financial assets and liabilities are classified into three categories: financial assets at fair value through profit or loss, financial assets at amortized cost, and financial assets at fair value through other comprehensive income. The Company's financial liabilities are classified into two categories: financial liabilities at fair value through profit or loss and financial liabilities at amortized cost. The Company's accounting policy for the recognition and measurement of financial assets and liabilities is consistent with the requirements of the International Financial Reporting Standards (IFRS) and the Chinese Accounting Standards (CAS).

(b) Amended the Company's accounting policy for the recognition and measurement of non-current assets and liabilities. The Company's non-current assets and liabilities are classified into two categories: non-current assets at fair value through profit or loss and non-current assets at fair value through other comprehensive income. The Company's non-current liabilities are classified into two categories: non-current liabilities at fair value through profit or loss and non-current liabilities at fair value through other comprehensive income. The Company's accounting policy for the recognition and measurement of non-current assets and liabilities is consistent with the requirements of the IFRS and the CAS.

(c) Amended the Company's accounting policy for the recognition and measurement of current assets and liabilities. The Company's current assets and liabilities are classified into two categories: current assets at fair value through profit or loss and current assets at fair value through other comprehensive income. The Company's current liabilities are classified into two categories: current liabilities at fair value through profit or loss and current liabilities at fair value through other comprehensive income. The Company's accounting policy for the recognition and measurement of current assets and liabilities is consistent with the requirements of the IFRS and the CAS.

D 30 2020, the Company's financial assets and liabilities are classified into three categories: financial assets at fair value through profit or loss, financial assets at amortized cost, and financial assets at fair value through other comprehensive income. The Company's financial liabilities are classified into two categories: financial liabilities at fair value through profit or loss and financial liabilities at amortized cost. The Company's accounting policy for the recognition and measurement of financial assets and liabilities is consistent with the requirements of the IFRS and the CAS.

(d) Amended the Company's accounting policy for the recognition and measurement of non-current assets and liabilities. The Company's non-current assets and liabilities are classified into two categories: non-current assets at fair value through profit or loss and non-current assets at fair value through other comprehensive income. The Company's non-current liabilities are classified into two categories: non-current liabilities at fair value through profit or loss and non-current liabilities at fair value through other comprehensive income. The Company's accounting policy for the recognition and measurement of non-current assets and liabilities is consistent with the requirements of the IFRS and the CAS.

Notes to Interim Condensed Consolidated

2020

30 2020

4. OPERATING SEGMENT INFORMATION (Continued)

Six months ended 30 June 2020 (unaudited)

	Pharmaceutical manufacturing and R&D RMB'000	Medical devices and medical diagnosis RMB'000	Healthcare Service RMB'000	Pharmaceutical distribution and retail RMB'000	Other business operations RMB'000	Adjustments and Eliminations RMB'000	Total RMB'000
Segment revenue:							
Revenue	9,952,096	2,638,887	1,359,017	—	15,179	—	13,965,179
Cost of sales	48,294	46,610	4,700	—	8,270	(107,874)	—
Revenue	10,000,390	2,685,497	1,363,717	—	23,449	(107,874)	13,965,179
Segment results*							
Operating profit	1,115,513	509,746	31,373	—	(4,289)	(19,026)	1,633,317
Operating expenses	135,673	10,551	16,910	—	16,579	—	179,713
Operating profit	157,704	14,210	3,393	—	275,233	30	450,570
Operating profit	56,129	10,345	17,531	—	185	(5,291)	78,899
Operating profit	(51,353)	(14,125)	(17,409)	—	(5,587)	26,170	(62,304)
Operating profit	27,605	(55,433)	(6,267)	—	(22,062)	—	(56,157)
Operating profit	(45,744)	—	—	—	(814)	—	(46,558)
Operating profit	32,681	24,021	(31,134)	724,041	(50,645)	—	698,964
Operating profit	—	—	—	—	—	—	171,305
Operating profit	—	—	—	—	—	—	(365,574)
Operating profit	—	—	—	—	—	—	(380,487)
Operating profit	1,428,208	499,315	14,397	724,041	208,600	1,883	2,301,688
Operating profit	(313,433)	(65,625)	(12,784)	—	(239)	—	(392,081)
Operating profit	1,114,775	433,690	1,613	724,041	208,361	1,883	1,909,607
Segment assets:							
Operating assets	41,047,332	8,262,367	9,812,781	13,877,770	4,251,314	(1,683,155)	75,568,409
Operating assets	349,474	—	—	—	6,730	—	356,204
Operating assets	2,248,581	1,102,609	1,624,283	13,877,770	2,859,201	—	21,712,444
Operating assets	—	—	—	—	—	—	4,544,467
Operating assets	—	—	—	—	—	—	80,112,876
Segment liabilities:							
Operating liabilities	18,654,179	1,937,780	2,229,824	—	386,141	(9,370,028)	13,837,896
Operating liabilities	—	—	—	—	—	—	26,476,159
Operating liabilities	—	—	—	—	—	—	40,314,055
Other segment information:							
Depreciation and amortization	590,999	96,170	133,901	—	15,197	—	836,267
Impairment loss	(32,251)	49,686	2,365	—	22,048	—	41,848
Goodwill impairment loss	1,309,447	97,984	356,886	—	47,953	—	1,812,270

* The segment results are calculated based on the accounting policies and methods used by the business units. The segment results are not necessarily comparable with the results of the business units.

** The segment results are calculated based on the accounting policies and methods used by the business units. The segment results are not necessarily comparable with the results of the business units.

Notes to Interim Condensed Consolidated

30 June 2020

30 June 2020

4. OPERATING SEGMENT INFORMATION (Continued)

Six months ended 30 June 2019 (unaudited)

	Revenue	Cost of sales	Gross profit	Operating expenses	Operating profit	Other income	Operating profit
	B'000	B'000	B'000	B'000	B'000	B'000	B'000
Segment revenue:							
Revenue	10,814,123	1,792,865	1,458,512		19,646		14,085,146
Cost of sales	8,421	19,401	1,876		20,674	(50,372)	
	10,822,544	1,812,266	1,460,388		40,320	(50,372)	14,085,146
Segment results*							
Revenue	1,204,721	291,795	168,982		10,328	(19,887)	1,655,939
Cost of sales	75,540	13,034	3,681		3,326		95,581
Gross profit	281,499	(3,481)	(748)	7,274	2,679		287,223
Operating expenses	50,628	16,153	21,874		216	(1,236)	87,635
Operating profit	(56,712)	(9,467)	(12,032)		(6,320)	29,102	(55,429)
Other income	(15,616)	(22,095)	(15,446)		1,121		(52,036)
Operating profit	(25,565)	477	(13,655)	774,939	(845)		(25,933)
Other income	37,529	(25,330)	(13,655)		(13,428)		760,055
Operating profit							115,621
Other income							(491,511)
Operating profit							(180,995)
Revenue	1,552,024	261,086	152,656	782,213	(2,923)	7,979	2,196,150
Cost of sales	(319,655)	(30,673)	(51,774)		(258)		(402,360)
Gross profit							25,839
Operating expenses							
Operating profit	1,232,369	230,413	100,882	782,213	(3,181)	7,979	1,819,629
Segment assets:							
Assets	36,425,494	6,874,258	10,781,464	12,429,996	4,362,843	(1,490,584)	69,383,471
Liabilities	399,018	12,808			9,134		420,960
Assets	2,153,707	948,143	3,232,275	12,429,996	3,085,411		21,849,532
Liabilities							4,249,250
Assets							73,632,721
Segment liabilities:							
Liabilities	15,346,659	1,505,277	1,698,142		281,002	(8,590,276)	10,240,804
Assets							28,931,431
Liabilities							39,172,235
Other segment information:							
Depreciation	502,504	85,220	133,338		19,190		740,252
Amortisation							
Impairment	2,435	19,425	6,493		(2,198)		26,155
Other	1,016,436	85,165	160,766		95,489		1,357,856

* Segment results are presented on a cost of sales basis. The segment results are presented on a cost of sales basis. The segment results are presented on a cost of sales basis.

** The segment results are presented on a cost of sales basis. The segment results are presented on a cost of sales basis. The segment results are presented on a cost of sales basis.

Condensed Consolidated

Revenue

Cost of sales

Information for revenue from contracts with customers

For the six months ended 30 June

2020 2019

RMB'000 B'000

(Unaudited) ()

13,951,418 14,066,560

13,761 18,586

13,965,179 14,085,146

Notes to Interim Condensed Consolidated

30 June 2020

30 June 2020

5. REVENUE (Continued)

For the six months ended 30 June 2019 (unaudited)

	Revenue	Cost of sales	Gross profit	Research and development	Net revenue
	B'000	B'000	B'000	B'000	B'000
Types of goods or services					
Revenue	10,564,090	1,671,542	27,181		12,262,813
Cost of sales	238,771	111,402	1,430,327	2,144	1,782,644
Revenue	11,182	9,921			21,103
Revenue	10,814,043	1,792,865	1,457,508	2,144	14,066,560
Geographical markets					
Revenue	8,288,825	1,024,242	1,457,508	406	10,770,981
Cost of sales	2,525,218	768,623		1,738	3,295,579
Revenue	10,814,043	1,792,865	1,457,508	2,144	14,066,560
Timing of revenue recognition					
Revenue	10,575,272	1,681,463	27,181		12,283,916
Cost of sales	128,209	41,595	1,430,327	2,144	1,602,275
Revenue	110,562	69,807			180,369
Revenue	10,814,043	1,792,865	1,457,508	2,144	14,066,560

Notes to Interim Condensed Consolidated

2020

30 2020

6. OTHER INCOME

		For the six months ended 30 June	
		2020	2019
		RMB'000	B'000
		(Unaudited)	()
D	20,391	17,523	
	158,367	92,104	
	1,671	97	
	180,429	109,724	

7. OTHER GAINS

		For the six months ended 30 June	
		2020	2019
		RMB'000	B'000
		(Unaudited)	()
	87,209	27,528	
	439,102	327,405	
	—	2,186	
	77,311	32,567	
		603,622	389,686

8. FINANCE COSTS

		For the six months ended 30 June	
		2020	2019
		RMB'000	B'000
		(Unaudited)	()
	425,687	543,161	
	12,188	12,355	
	(9,997)	(8,576)	
	427,878	546,940	

9. PROFIT BEFORE TAX

For the six months ended 30 June

	2020 RMB'000 (Unaudited)	2019 B'000 ()
C	4,932,900	4,263,438
C	1,282,972	1,335,545
5. 2. 1. () D 's 'a C ' m a) 5. 2. 1. a a m : D A m m a : D 5. 2. 1. - a a m	2,468,297 66,453 83,795 39,516	1,952,209 134,290 67,904 46,956
	2,658,061	2,201,359
a a m : C : m a &D * a a	1,167,594 46,028	816,188 12,128
	1,121,566	804,060
a m m a m a a D a , a a m D a - - a Am a a a (a)/ m a m a , a a m m a m a a a a a a a a a a a a , a a , a a m	12,963 490,945 91,076 254,247 (917) 42,765 (439,102) (69,551) (1,621)	10,981 458,599 74,916 206,737 4,237 21,918 (327,405) (6,028) (18,465)

[illegible]

Notes to Interim Condensed Consolidated

30 2020

10. INCOME TAX

2020年6月30日止期间，本公司适用的企业所得税率为25%（2019年：25%）。
2008年1月1日起，本公司适用的企业所得税率为25%。2008年1月1日之前，本公司适用的企业所得税率为0%。

2020年6月30日止期间，本公司适用的企业所得税率为25%（2019年：25%）。
2008年1月1日起，本公司适用的企业所得税率为25%。2008年1月1日之前，本公司适用的企业所得税率为0%。

2020年6月30日止期间，本公司适用的企业所得税率为25%（2019年：25%）。
2008年1月1日起，本公司适用的企业所得税率为25%。2008年1月1日之前，本公司适用的企业所得税率为0%。

	For the six months ended 30 June	
	2020 RMB'000 (Unaudited)	2019 RMB'000 (Unaudited)
C	467,327	464,045
D	(75,246)	(87,524)
	392,081	376,521

11. DIVIDENDS

2020年6月30日止期间，本公司适用的企业所得税率为25%（2019年：25%）。
2008年1月1日起，本公司适用的企业所得税率为25%。2008年1月1日之前，本公司适用的企业所得税率为0%。

1 2 3 4

12. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

[illegible]

13. PROPERTY, PLANT AND EQUIPMENT

Ca	30	2020	11,313,846
----	----	------	------------

▼ B217,305,000 (31 D 2019: ▼ B133,709,000), 16

30 June 2020 RMB'000 (Unaudited)

[illegible]

Notes to Interim Condensed Consolidated

2020 2019 2018 2017

30 June 2020

14. TRADE AND BILLS RECEIVABLES (Continued)

A 2020, 2019, 2018, 2017		30 June 2020 RMB'000 (Unaudited)	31 Dec 2019 B'000 (A)
1 2020, 2019, 2018, 2017		4,999,855	4,302,722
2 2020, 2019, 2018, 2017		144,630	111,346
3 2020, 2019, 2018, 2017		67,601	61,584
3 2020, 2019, 2018, 2017		125,446	114,549
2020, 2019, 2018, 2017		5,337,532 (256,987)	4,590,201 (222,601)
2020, 2019, 2018, 2017		5,080,545	4,367,600
A 30 2020, 2019, 2018, 2017		B5,300,000 (2019: B8,146,000)	

15. TRADE AND BILLS PAYABLES

A 2020, 2019, 2018, 2017		30 June 2020 RMB'000 (Unaudited)	31 Dec 2019 B'000 (A)
2020, 2019, 2018, 2017		2,566,965	2,152,747
B 2020, 2019, 2018, 2017		297,052	244,568
2020, 2019, 2018, 2017		2,864,017	2,397,315
2020, 2019, 2018, 2017			
A 2020, 2019, 2018, 2017			
2020, 2019, 2018, 2017		2,516,937	2,105,194
2 2020, 2019, 2018, 2017		34,054	36,473
3 2020, 2019, 2018, 2017		9,155	3,082
3 2020, 2019, 2018, 2017		6,819	7,998
2020, 2019, 2018, 2017		2,566,965	2,152,747

Notes to Interim Condensed Consolidated

2020

30 2020

16. INTEREST-BEARING BANK AND OTHER BORROWINGS

		30 June 2020 RMB'000 (Unaudited)	31 Dec 2019 RMB'000 (Audited)
Bank borrowings:	(1)	486,008	344,186
		15,096,396	13,762,714
		15,582,404	14,106,900
Other borrowings:	(2)	899,616	7,030,209
	(3)	6,876,099	7,030,209
		23,358,119	21,137,109
		(12,404,601)	(8,560,202)
		10,953,518	12,576,907
Analysis of bank and other borrowings:			
		30 June 2020 RMB'000 (Unaudited)	31 Dec 2019 RMB'000 (Audited)
Bank borrowings:			
1. Short-term bank borrowings		12,404,601	8,560,202
2. Long-term bank borrowings		7,833,867	6,860,077
3. Other bank borrowings		2,633,443	5,395,435
4. Other bank borrowings		486,208	321,395
		23,358,119	21,137,109
		(12,404,601)	(8,560,202)
		10,953,518	12,576,907

1 2 3 4

16. INTEREST-BEARING BANK AND OTHER BORROWINGS (Continued)

[illegible]

2	▼	A	2020,	C	m	a	-	m	m	a	v	v	v	v	v	v	B600,000,000,	w	v	2.50%
a	m.	S	S	-	m	C	m	m	v	v	v	v	v	v	v	v	27	m	2020.	

8	▼	A	2020,	C	m	a	-	m	m	a	v	v	v	v	v	v	B300,000,000,	w	v	2.20%
a	m.	S	S	-	m	C	m	m	v	v	v	v	v	v	v	v	7	m	2020.	

අංකය	විස්තරය	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986	1985	1984	1983	1982	1981	1980	1979	1978	1977	1976	1975	1974	1973	1972	1971	1970	1969	1968	1967	1966	1965	1964	1963	1962	1961	1960	1959	1958	1957	1956	1955	1954	1953	1952	1951	1950	1949	1948	1947	1946	1945	1944	1943	1942	1941	1940	1939	1938	1937	1936	1935	1934	1933	1932	1931	1930	1929	1928	1927	1926	1925	1924	1923	1922	1921	1920	1919	1918	1917	1916	1915	1914	1913	1912	1911	1910	1909	1908	1907	1906	1905	1904	1903	1902	1901	1900	1899	1898	1897	1896	1895	1894	1893	1892	1891	1890	1889	1888	1887	1886	1885	1884	1883	1882	1881	1880	1879	1878	1877	1876	1875	1874	1873	1872	1871	1870	1869	1868	1867	1866	1865	1864	1863	1862	1861	1860	1859	1858	1857	1856	1855	1854	1853	1852	1851	1850	1849	1848	1847	1846	1845	1844	1843	1842	1841	1840	1839	1838	1837	1836	1835	1834	1833	1832	1831	1830	1829	1828	1827	1826	1825	1824	1823	1822	1821	1820	1819	1818	1817	1816	1815	1814	1813	1812	1811	1810	1809	1808	1807	1806	1805	1804	1803	1802	1801	1800	1799	1798	1797	1796	1795	1794	1793	1792	1791	1790	1789	1788	1787	1786	1785	1784	1783	1782	1781	1780	1779	1778	1777	1776	1775	1774	1773	1772	1771	1770	1769	1768	1767	1766	1765	1764	1763	1762	1761	1760	1759	1758	1757	1756	1755	1754	1753	1752	1751	1750	1749	1748	1747	1746	1745	1744	1743	1742	1741	1740	1739	1738	1737	1736	1735	1734	1733	1732	1731	1730	1729	1728	1727	1726	1725	1724	1723	1722	1721	1720	1719	1718	1717	1716	1715	1714	1713	1712	1711	1710	1709	1708	1707	1706	1705	1704	1703	1702	1701	1700	1699	1698	1697	1696	1695	1694	1693	1692	1691	1690	1689	1688	1687	1686	1685	1684	1683	1682	1681	1680	1679	1678	1677	1676	1675	1674	1673	1672	1671	1670	1669	1668	1667	1666	1665	1664	1663	1662	1661	1660	1659	1658	1657	1656	1655	1654	1653	1652	1651	1650	1649	1648	1647	1646	1645	1644	1643	1642	1641	1640	1639	1638	1637	1636	1635	1634	1633	1632	1631	1630	1629	1628	1627	1626	1625	1624	1623	1622	1621	1620	1619	1618	1617	
------	---------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	--

17. BUSINESS COMBINATION

[illegible]

$\frac{W}{\sqrt{N}}$: $\frac{W}{\sqrt{N}}$: $\frac{W}{\sqrt{N}}$: $\frac{W}{\sqrt{N}}$: $\frac{W}{\sqrt{N}}$: $\frac{W}{\sqrt{N}}$: $\frac{W}{\sqrt{N}}$:

[illegible]

1 2 3 4

17. BUSINESS COMBINATION (Continued)

18. COMMITMENTS

30 June 2020
RMB'000
(audited)

Notes to Interim Condensed Consolidated

2020

30 2020

19. RELATED PARTY TRANSACTIONS

For the six months ended 30 June

(a) Sales of pharmaceutical products and services

	2020 RMB'000 (Unaudited)	2019 RMB'000 (Unaudited)
For the six months ended 30 June		
2020		
2019		
1,395,932	1,567,956	
188,335	205,246	
98,576	216	
92,686	49,757	
68,855	42,836	
7,036	32,492	
4,315		
4,030	3,256	
2,555	1,453	
1,777	22	
1,612	4,702	
1,262		
737	1,575	
406	148	
42		
16		
16	17	
14	12	
13	60	
3		
—	17	
—	1	
1,868,218	1,909,766	

Notes to Interim Condensed Consolidated

2020 2019

30 June 2020

19. RELATED PARTY TRANSACTIONS (Continued)

(b) Purchase of pharmaceutical products and services

	Six months ended 30 June	
	2020 RMB'000 (Unaudited)	2019 RMB'000 (Unaudited)
From C. J. J. (4 & 6 & 15)	128,644	125,937
From C. J. J. (3 & 4 & 11 & 16)	96,578	1,156
From C. J. J. (4 &)	87,769	8,899
From C. J. J. (1 & 4 & 16)	2,266	410
From A. J. J. (1 & 4)	1,071	1,164
From A. J. J. (1 & 4)	1,007	2,126
From D. J. J. (2 & 4 & 17)	907	85
From D. J. J. (4 &)	510	3,352
From D. J. J. (4 &)	33	
From C. J. J. (1 & 4)	23	
From B. J. J. (1 & 4)	—	1,318
From C. J. J. (1 & 4 & 1)	—	1,228
	318,808	145,675

(c) Leasing and property management services

	Six months ended 30 June	
	2020 RMB'000 (Unaudited)	2019 RMB'000 (Unaudited)
As lessor		
From B. J. J. (2 & 5)	6,106	5,310
From C. J. J. (3 & 5 & 12 & 16)	3,529	7,895
From C. J. J. (1 & 5)	733	
From D. J. J. (2 & 5 & 17)	578	325
From D. J. J. (5 & 7)	471	454
From C. J. J. (1 & 5 & 6)	413	131
From C. J. J. (2 & 5)	216	
From C. J. J. (1 & 5)	145	86
From C. J. J. (1 & 5)	65	
From C. J. J. (1 & 5)	—	264
	12,256	14,465

19. RELATED PARTY TRANSACTIONS (Continued)

	Six months ended 30 June	
	2020	2019
	RMB'000	B'000
As lessee	(Unaudited)	(Audited)
Operating lease	2,952	5,477
Finance lease	117	114
Short-term lease	43	41
Lease with purchase option	—	2,500
	3,112	8,132

	Six months ended 30 June	
	2020	2019
	RMB'000	B'000
	(Unaudited)	(Audited)
Property management services	6,904	6,651

C M A A B A A M W A C A M (A),

A A A A A C M A A A ,

, M A A A A A A C A B A K A C M M A M

1 A A 2020 A 31 D M 2022. M A M M A A A A A W

A ▼B1,000,000,000. M A M M A A A A A A

▼B1,000,000,000.

	Six months ended 30 June	
	2020	2019
	RMB'000	B'000
Maximum daily outstanding balance of deposits in Fosun Finance	(Unaudited)	()
9 C 9 M (& 16)	979,619	574,422

Notes to Interim Condensed Consolidated

30 June 2020

30 June 2020

19. RELATED PARTY TRANSACTIONS (Continued)

(d) Loans from/to related parties (Continued)

	30 June 2020 RMB'000 (Unaudited)	31 Dec 2019 RMB'000 (Audited)
A loan from a related party		
Loan from C, M (1 & 16)	52,274	38,779
Loan from C, M (1 & 16) at 3%.		
Loan from D, M (1 & 16) at 10%.		
Loan from D, M (1 & 16) at 10%.		

	30 June 2020 RMB'000 (Unaudited)	31 Dec 2019 RMB'000 (Audited)
Loans to related parties		
Loan to C, M (1 & 16)	10,884	10,566
Loan to B, C, M (2 & 16)	188,840	188,840
	199,724	199,406

(e) Interest income from/to related parties

	Six months ended 30 June 2020 RMB'000 (Unaudited)	2019 RMB'000 (Audited)
Interest income		
Interest income from B, C, M (2 & 16)	4,706	2,002
Interest income from C, M (1 & 16)	3,358	1,845
Interest income from D, M (1 & 16)	160	154
	8,224	4,001

Notes to Interim Condensed Consolidated

2020

30 2020

19. RELATED PARTY TRANSACTIONS (Continued)

(e) Interest income from/to related parties (Continued)

During the six months ended 30 June 2020, the Group's interest income from/to related parties was RMB1,058,000 (2019: RMB1,619,000). The interest income from/to related parties was calculated at the market rate of 3%.

	Six months ended 30 June	
	2020 RMB'000 (Unaudited)	2019 RMB'000 (Unaudited)
Interest expense	1,058	1,619

- (1) The interest income from/to related parties was calculated at the market rate of 3%.
- (2) The interest income from/to related parties was calculated at the market rate of 3%.
- (3) The interest income from/to related parties was calculated at the market rate of 3%.
- (4) The interest income from/to related parties was calculated at the market rate of 3%.
- (5) The interest income from/to related parties was calculated at the market rate of 3%.
- (6) The interest income from/to related parties was calculated at the market rate of 3%.
- (7) The interest income from/to related parties was calculated at the market rate of 3%.
- (8) The interest income from/to related parties was calculated at the market rate of 3%.
- (9) The interest income from/to related parties was calculated at the market rate of 3%.
- (10) D, the interest income from/to related parties was calculated at the market rate of 3%.
- (11) D, the interest income from/to related parties was calculated at the market rate of 3%.
- (12) D, the interest income from/to related parties was calculated at the market rate of 3%.
- (13) D, the interest income from/to related parties was calculated at the market rate of 3%.

71

Notes to Interim Condensed Consolidated

30 2020

19. RELATED PARTY TRANSACTIONS (Continued)

(g) Outstanding balances with related parties (Continued)

() A 30 2020, 881,705,000

1 2 3 4

20. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

[illegible][illegible][illegible][illegible][illegible][illegible]

Notes to Interim Condensed Consolidated

30 2020

20. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Unobservable inputs for Level 3 liabilities (Continued)

30 2020 30 2019: B2,643,984,000 (31 D 2019: B2,818,244,000) B DA (B , , D A) 2018, B DA 2019.

Fair value hierarchy

Assets measured at fair value:

30 2020 ()

	Quoted prices in active markets (Level 1) RMB'000	Fair value measurement using Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	Total RMB'000
30 2020	566	849	59,530	60,945
30 2020	1,097,737	52,959	1,694,007	2,844,703
D 30 2020	—	354,915	—	354,915
30 2020	1,098,303	408,723	1,753,537	3,260,563

31 201 ()

	(1) B'000	(2) B'000	(3) B'000	B'000
30 2020	1,554	52,909	53,246	107,709
30 2020	561,348	52,734	1,825,724	2,439,806
D 30 2020	—	445,103	—	445,103
30 2020	562,902	550,746	1,878,970	2,992,618

১৯৯১

75

Notes to Interim Condensed Consolidated

30 2020

20. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Fair value hierarchy (Continued)

Liabilities measured at fair value:

30 2020 ()

	Quoted prices in active markets (Level 1) RMB'000	Fair value measurement using Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	Total RMB'000
Am - m a	—	—	2,643,984	2,643,984

31 201 ()

	Quoted prices in active markets (Level 1) RMB'000	Fair value measurement using Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	Total RMB'000
Am - m a	—	—	2,643,984	2,643,984
Am - m a	—	—	2,608,958	2,608,958
Am - m a	—	—	2,818,244	2,818,244

m m a a m a m 3 f a a w :

	Six months ended 30 June 2020 RMB'000 (Unaudited)	2019 RMB'000 ()
A a 1 a a	2,818,244	2,913,876
A	35,026	46,708
D a	(209,286)	
A a 30	2,643,984	2,960,584

D , w a a a m a m w 1 a 2(m 30 2019: a).

21. CONTINGENT LIABILITIES

As at 30 June 2020, there were no contingent liabilities as at 30 June 2019.

22. EVENTS AFTER THE REPORTING PERIOD

There were no events after the reporting period.

23. APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The interim condensed consolidated financial statements were approved by the Board of Directors on 25 August 2020.

[illegible]

Definitions

[illegible]

Definitions

§	C mm	§	C mm	C m a
§ a	W ■ a/	§ a	W ■ a C ., .*	(宿遷市鐘吾醫院有限責任公司), a C a ■ a* (宿遷市腫瘤醫院), a a C m a
§ a	a a ■ a	§ a	a a a a ▼ a a m a	C m a m * (宿遷市新星康復體檢有限公司), a a C m a
§.	§ a	§ a	A m a, a	, a § a § a a
§ a	, § D § \$	D	C m a	
§ a		§ a		
§. DA		§.	a D A m a	
W a a f a m a		a	W a a B a m a a C m a m *	(江蘇萬邦生化醫藥集團有限責任公司), a a C m a
W a ■ a		W a	a ■ a m C m a *	(溫州老年病醫院有限公司), a a C m a
W		W ■ a a a		
W a ■ a		W a ■ a C ., .*	(武漢濟和醫院有限公司), a a C m a	
W C		W C § a a a D / a m	C m a *	(《董事有關僱員進行證券交易的書面指引》)
a f a m a		C a f a m a a C m a m *	(重慶藥友製藥有限責任公司), a a C m a	
a C a ■ a		a C a ■ a m *	(珠海禪誠醫院有限公司), a a C m a	
%				
, a		W C a m	, a , a a ,	
a C a W a		a C a a	a a , C a a a .	